Alkermes PLC (ALKS)
24.29
+0.06
(+0.25%)
USD |
NASDAQ |
Jul 05, 16:00
24.29
0.00 (0.00%)
After-Hours: 20:00
Alkermes Research and Development Expense (Annual): 270.81M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 270.81M |
| December 31, 2022 | 272.70M |
| December 31, 2021 | 290.92M |
| December 31, 2020 | 394.59M |
| December 31, 2019 | 512.83M |
| December 31, 2018 | 425.41M |
| December 31, 2017 | 412.89M |
| December 31, 2016 | 387.15M |
| December 31, 2015 | 344.40M |
| December 31, 2014 | 272.04M |
| December 31, 2013 | 128.12M |
| March 31, 2013 | 140.01M |
| March 31, 2012 | 141.89M |
| March 31, 2011 | 97.24M |
| March 31, 2010 | 95.36M |
| March 31, 2009 | 89.48M |
| Date | Value |
|---|---|
| March 31, 2008 | 125.27M |
| March 31, 2007 | 117.32M |
| March 31, 2006 | 89.07M |
| March 31, 2005 | 91.64M |
| March 31, 2004 | 91.10M |
| March 31, 2003 | 85.39M |
| March 31, 2002 | 92.09M |
| March 31, 2001 | 68.77M |
| March 31, 2000 | 54.48M |
| March 31, 1999 | 48.50M |
| March 31, 1998 | 31.76M |
| March 31, 1997 | 29.55M |
| March 31, 1996 | 21.59M |
| March 31, 1995 | 19.00M |
| March 31, 1994 | 20.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
270.81M
Minimum
2023
512.83M
Maximum
2019
348.37M
Average
290.92M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Jazz Pharmaceuticals PLC | 849.66M |
| Medtronic PLC | 2.735B |
| Perrigo Co PLC | 122.50M |
| Trinity Biotech PLC | 4.379M |
| Iterum Therapeutics PLC | 39.99M |